Guillain-Barre syndrome is a rare but serious condition which needs urgent treatment in hospital to prevent it progressing.

Pfizer's revenue slump is temporary. New launches and Seagen integration drive 2025 growth. Read here for an investment ...

The medicines regulator has issued a warning to NHS health staff about a small increased risk of a rare condition affecting ...

The Food and Drug Administration has approved three vaccines for RSV — GSK's GSK.L Arexvy, Moderna's MRNA.O mRESVIA and ...

Pfizer’s vaccine – called Abrysvo – is indicated for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years and older, the same label that the FDA gave to ...

Pregnant patients also have access to Pfizer’s RSV vaccine Abrysvo, which is recommended for pregnant people to protect newborns from lower respiratory infections.

Pfizer is also running a phase 3 trial of Abrysvo in adults aged 18 to 59 at elevated risk of RSV disease due to chronic medical conditions, but data from that isn't due until later this year.

Gilead Sciences has blamed the low rate of respiratory syncytial virus (RSV) infections last season for ending two midstage ...

The expanded recommendation is good news for Moderna, Pfizer, and GSK, which all sell RSV vaccines for older adults. Moderna ...

GSK’s Arexvy and Pfizer’s Abrysvo are the top-selling RSV vaccines for older adults and will be joined in the next RSV season by Moderna’s recently approved mRESVIA. Meanwhile, Sanofi and AZ ...

Pfizer ’s PFE Abrysvo is approved for the prevention of RSV-associated LRTD in all individuals aged 60 years and above, as well as in infants, through maternal immunization.